Clinical Utility of Optical Genome Mapping for Improved Cytogenomic Analysis of Gliomas
Authors:
- Harmanpreet SinghHSHarmanpreet Singh
- Nikhil S. SahajpalNSNikhil S. Sahajpal
- Ashis K. MondalAMAshis K. Mondal
- Stephanie L. BurkeSBStephanie L. Burke
- Jaspreet FarmahaJFJaspreet Farmaha
- Ahmet AlptekinAAAhmet Alptekin
- Ashutosh VashishtAVAshutosh Vashisht
- Kimya JonesKJKimya Jones
- Vishakha VashishtVVVishakha Vashisht
- Ravindra KolheRKRavindra Kolhe
Open Access
- 25 July 2024
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 12 (8) , 1659
Abstract
A glioma is a solid brain tumor which originates in the brain or brain stem area. The diagnosis of gliomas based on standard-of-care (SOC) techniques includes karyotyping, fluorescence in situ hybridization (FISH), and chromosomal microarray (CMA), for detecting the pathogenic variants and chromosomal abnormalities. But these techniques do not reveal the complete picture of genetic complexity, thus requiring an alternative technology for better characterization of these tumors. The present study aimed to evaluate the clinical performance and feasibility of using optical genome mapping (OGM) for chromosomal characterization of gliomas. Herein, we evaluated 10 cases of gliomas that were previously characterized by CMA. OGM analysis showed concordance with the results of CMA in identifying the characterized Structural Variants (SVs) in these cases. More notably, it also revealed additional clinically relevant aberrations, demonstrating a higher resolution and sensitivity. These clinically relevant SVs included cryptic translocation, and SVs which are beyond the detection capabilities of CMA. Our analysis highlights the unique capability of OGM to detect all classes of SVs within a single assay, thereby unveiling clinically significant data with a shorter turnaround time. Adopting this diagnostic tool as a standard of care for solid tumors like gliomas shows potential for improving therapeutic management, potentially leading to more personalized and timely interventions for patients.Keywords
This publication has 15 references indexed in Scilit:
- Prospective Investigation of Optical Genome Mapping for Prenatal Genetic DiagnosisClinical Chemistry, 2024
- Optical genome mapping in acute myeloid leukemia: a multicenter evaluationBlood Advances, 2023
- ADAMTS1 as potential prognostic biomarker promotes malignant invasion of gliomaInternational Journal of Clinical Oncology, 2022
- Clinical Validation and Diagnostic Utility of Optical Genome Mapping for Enhanced Cytogenomic Analysis of Hematological NeoplasmsThe Journal of Molecular Diagnostics, 2022
- Next-generation cytogenetics: Comprehensive assessment of 52 hematological malignancy genomes by optical genome mappingThe American Journal of Human Genetics, 2021
- Optical genome mapping enables constitutional chromosomal aberration detectionThe American Journal of Human Genetics, 2021
- The 2021 WHO Classification of Tumors of the Central Nervous System: a summaryNeuro-Oncology, 2021
- Prognostic factors of patients with Gliomas – an analysis on 335 patients with Glioblastoma and other forms of GliomasBMC Cancer, 2020
- Epidemiology of Brain TumorsNeurologic Clinics, 2016
- Comparison of chromosome analysis and chromosomal microarray analysis: what is the value of chromosome analysis in today’s genomic array era?Genetics in Medicine, 2013